Company news

Neurotech International Ltd. news in 2023

Neurotech International Ltd.'s news releases, calls and decks from 2023, newest first.

View company

Phase II/III Autism Clinical Trial Completes Recruitment

December 18, 2023

HREC Approval to Extend Phase II/III ASD Trial to Adults

December 3, 2023

Neurotech Receives $3.17 Million R&D Tax Incentive Refund

November 14, 2023

Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint

October 5, 2023

Completion of Patient Recruitment in NTIRTT1 Clinical Trial

September 26, 2023

Last Patient Completes Treatment in NTIPANS1 Clinical Trial

August 30, 2023

Appendix 4E & Annual Report

August 30, 2023

First Patient Treated in Rett Syndrome Clinical Trial

August 1, 2023

NTI Receives HREC Approval for Rett Syndrome Clinical Trial

July 9, 2023

NTI Granted 2 Year Extension of Treatment for ASD Patients

May 30, 2023

NTI granted HREC Approval for PANDAS/PANS Trial Extension

May 29, 2023

NTI Completes Recruitment in PANDAS/PANS Clinical Trial

May 2, 2023

NTI to Launch Phase II Clinical Trial in Rett Syndrome

March 19, 2023

Phase I/II ASD Clinical Trials Results at 52 Weeks

March 16, 2023

First Patient Treated in Phase I/II PANDAS/PANS Trial

February 16, 2023

Approval for Additional Phase I/II ASD Trial Extension

February 13, 2023

HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

January 26, 2023

NTI Granted FDA Pre-IND Meeting for NTI164 in ASD

January 19, 2023

Decks in 2023